Alere's Triage tests facing potential recall after FDA warning
This article was originally published in Clinica
Executive Summary
Alere's Triage cardiology and toxicology tests could be recalled, after the US FDA sent the company a subpoena relating to quality control testing and performance of the diagnostics. Although the company did not put a figure on the financial impact of a potential recall, Canaccord Genuity analyst Jeffrey Frelick noted that the FDA appears to be focused on the firm's Triage multi-marker cardiology tests, which contribute around $20m of revenues per quarter.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.